REGENXBIO (NASDAQ:RGNX) Given "Buy" Rating at Chardan Capital

Chardan Capital reiterated their buy rating on shares of REGENXBIO (NASDAQ:RGNX - Free Report) in a report published on Thursday morning,Benzinga reports. They currently have a $52.00 target price on the biotechnology company's stock.

Other research analysts also recently issued research reports about the stock. The Goldman Sachs Group downgraded shares of REGENXBIO from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Morgan Stanley upped their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Raymond James began coverage on REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $33.88.

Remove Ads

REGENXBIO Price Performance

Shares of NASDAQ:RGNX traded up $0.46 during trading on Thursday, reaching $8.70. The stock had a trading volume of 780,919 shares, compared to its average volume of 711,321. The stock has a market capitalization of $435.75 million, a PE ratio of -1.73 and a beta of 1.35. REGENXBIO has a 52 week low of $5.62 and a 52 week high of $22.42. The business's 50-day moving average price is $7.34 and its 200 day moving average price is $8.85.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Analysts forecast that REGENXBIO will post -4.84 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RGNX. FMR LLC grew its stake in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,656 shares during the period. GAMMA Investing LLC boosted its holdings in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after buying an additional 2,510 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of REGENXBIO during the 4th quarter worth about $54,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of REGENXBIO in the 4th quarter valued at about $79,000. Finally, Laurion Capital Management LP bought a new stake in shares of REGENXBIO in the 4th quarter valued at about $79,000. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.